Inotuzumab ozogamicin is an antibody-drug conjugate targeting CD22, composed of a humanized anti-CD22 antibody linked to the cytotoxic agent Calicheamicin. This compound exhibits potent efficacy against CD22-positive B-cell non-Hodgkin’s lymphoma and is being investigated for its potential in treating acute lymphoblastic leukemia. Researchers can utilize Inotuzumab ozogamicin to explore therapeutic strategies for CD22-expressing malignancies.
Inotuzumab ozogamicin is an antibody-drug conjugate targeting CD22, composed of a humanized anti-CD22 antibody linked to the cytotoxic agent Calicheamicin. This compound exhibits potent efficacy against CD22-positive B-cell non-Hodgkin’s lymphoma and is being investigated for its potential in treating acute lymphoblastic leukemia. Researchers can utilize Inotuzumab ozogamicin to explore therapeutic strategies for CD22-expressing malignancies.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
